Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

SkinHealth Systems Inc.

SKIN Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2019โ€“FY2025

Last close ยท Oct 23, 2026

$10.88

1.9%
Compare
Revenue Total sales reported in the income statement.
$301M
10.0% vs prior year
Operating margin Operating income as a share of revenue.
โˆ’6.9%
13.4ย pts
Net income Profit after all expenses, interest and tax.
โˆ’$9.5M
Free cash flow Cash from operations minus capital spending.
$37.2M
141.8%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$1.4B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$0.18 EPS (TTM)

What SkinHealth Systems Inc. does

No business description yet.

Legal name
SkinHealth Systems Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Mar 12, 2026
Accession ยท CIK
0001628280-26-017376
0001818093

Revenue and margins

SkinHealth Systems Inc. had $301M of revenue in fiscal 2025, down 10.0% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $37.2M in fiscal 2025, 12.4% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

SkinHealth Systems Inc. returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count fell 4.7%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably SkinHealth Systems Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $902M$568M$523M$370M$233M
Debt incl. finance leases โ€”โ€”โ€”$552Mโ€”
Debt / equity โ€”โ€”โ€”10.7xโ€”
Interest coverage โˆ’3.4xโˆ’1.9xโˆ’9.6xโˆ’6.5xโˆ’1.1x
Current ratio 13.1x10.9x6.1x7.0x1.7x
Quick ratio 12.6x9.4x5.3x6.0x1.4x
Total assets $1.2B$1.0B$929M$686M$500M
Total liabilities $917M$836M$870M$634M$439M
Shareholders' equity $298M$167M$59.4M$51.8M$61.1M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”$182Mโ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ“ โœ• โœ• โœ•
Cash from operations is positive โœ“ โœ• โœ• โœ• โœ“ โœ“ โœ“
Return on assets rose โ€” โ€” โœ• โœ“ โœ• โœ“ โœ“
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ• โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โ€” โœ“ โœ• โœ• โœ“ โœ•
Share count didn't rise โ€” โœ• โœ• โœ• โœ“ โœ• โœ“
Gross margin rose โ€” โœ• โœ“ โœ• โœ• โœ“ โœ“
Revenue rose relative to assets โ€” โ€” โœ• โœ“ โœ“ โœ“ โœ“
F-score โ€” / 3โ€” / 53 / 83 / 84 / 86 / 86 / 8
Accruals ratio โ€”โˆ’7.5%โˆ’48.6%13.6%โˆ’12.6%โˆ’5.6%โˆ’7.9%
Altman Z'' โ€”โˆ’0.453.983.461.560.92โˆ’1.89

7 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $167M $119M $260M $366M $398M $334M $301M
Gross profit $107M $67.2M $179M $249M $155M $182M $196M
Research and development $4.6M $3.4M $8.2M $8.4M $10.1M $6.3M $5.6M
Operating income $13.5M โˆ’$17.2M โˆ’$39.9M โˆ’$25.8M โˆ’$131M โˆ’$67.8M โˆ’$20.8M
Interest expense โ€” โ€” $11.8M $13.4M $13.6M $10.4M $19.3M
Pretax income โˆ’$2.9M โˆ’$38.5M โˆ’$381M $45.3M โˆ’$102M โˆ’$29.6M โˆ’$5.9M
Income tax โˆ’$1.3M โˆ’$9.3M โˆ’$1.9M $1.1M โˆ’$1.8M โˆ’$0.5M $3.6M
Net income โˆ’$1.6M โˆ’$29.2M โˆ’$379M $44.2M โˆ’$100M โˆ’$29.1M โˆ’$9.5M
Net income to common โ€” โˆ’$29.2M โˆ’$379M $44.2M โˆ’$100M โˆ’$29.1M โˆ’$9.5M
Diluted EPS โˆ’$0.05 โˆ’$0.85 โˆ’$3.71 โˆ’$0.23 โˆ’$0.76 โˆ’$0.36 โˆ’$0.16
Diluted shares 0.03B 0.03B 0.10B 0.15B 0.13B 0.14B 0.14B
Cash flow
Cash from operations $1.7M โˆ’$12.4M โˆ’$28.4M โˆ’$107M $21.8M $16.1M $37.5M
Capital expenditure $8.8M $3.5M $11.2M $10.8M $3.8M $0.8M $0.3M
Free cash flow โˆ’$7.0M โˆ’$15.9M โˆ’$39.6M โˆ’$117M $17.9M $15.4M $37.2M
Depreciation and amortization $1.4M $2.6M $4.5M $7.2M $11.3M $9.9M $3.8M
Stock-based compensation $0.1M $0.4M $12.4M $28.5M $22.5M $26.7M $14.8M
Acquisitions $2.1M $0.0M $22.9M $0.0M โ€” โ€” โ€”
Share buybacks $0.0M $0.2M $0.0M $160M $30.2M $0.0M $0.0M
Dividends and buybacks $0.0M $0.2M $0.0M $160M $30.2M $0.0M $0.0M
Balance sheet
Cash and short-term investments $7.3M $9.5M $902M $568M $523M $370M $233M
Total debt โ€” โ€” โ€” โ€” โ€” $552M โ€”
Current assets โ€” $59.1M $1.0B $783M $698M $477M $310M
Current liabilities โ€” $30.9M $76.4M $71.7M $115M $68.2M $186M
Inventory โ€” $23.2M $35.3M $110M $91.3M $69.1M $48.0M
Property and equipment, net โ€” $9.2M โ€” โ€” โ€” โ€” โ€”
Goodwill $98.5M $98.5M $124M $125M $126M $123M $127M
Intangible assets โ€” $50.9M $56.0M $46.4M $62.1M $47.5M $35.8M
Total assets โ€” $223M $1.2B $1.0B $929M $686M $500M
Total liabilities โ€” $253M $917M $836M $870M $634M $439M
Preferred stock โ€” $0.0M $0.0M $0.0M โ€” โ€” โ€”
Shareholders' equity โˆ’$1.2M โˆ’$30.6M $298M $167M $59.4M $51.8M $61.1M
Margins
Gross margin 63.9% 56.4% 68.6% 68.0% 39.0% 54.5% 65.3%
Operating margin 8.1% โˆ’14.4% โˆ’15.4% โˆ’7.1% โˆ’32.9% โˆ’20.3% โˆ’6.9%
EBITDA margin 8.9% โˆ’12.3% โˆ’13.6% โˆ’5.1% โˆ’30.0% โˆ’17.3% โˆ’5.6%
Net margin โˆ’1.0% โˆ’24.5% โˆ’145.6% 12.1% โˆ’25.2% โˆ’8.7% โˆ’3.2%
FCF margin โˆ’4.2% โˆ’13.4% โˆ’15.2% โˆ’32.1% 4.5% 4.6% 12.4%
Returns
Return on capital โ€” โ€” โ€” โ€” โ€” โˆ’22.9% โ€”
Return on capital employed โ€” โˆ’9.0% โˆ’3.5% โˆ’2.8% โˆ’16.1% โˆ’11.0% โˆ’6.6%
Return on equity โ€” โ€” โˆ’283.2% 19.0% โˆ’88.4% โˆ’52.3% โˆ’16.9%
Return on assets โ€” โˆ’13.1% โˆ’52.5% 4.0% โˆ’10.4% โˆ’3.6% โˆ’1.6%
Return on tangible equity โ€” โ€” โˆ’320.1% โ€” โ€” โ€” โ€”
Growth
Revenue growth โ€” โˆ’28.5% 118.4% 40.7% 8.8% โˆ’16.0% โˆ’10.0%
Net income growth โ€” โ€” โ€” โ€” โˆ’326.4% โ€” โ€”
FCF growth โ€” โ€” โ€” โ€” โ€” โˆ’14.2% 141.8%
Share count change โ€” 6.7% 197.8% 45.4% โˆ’11.3% 8.2% โˆ’4.7%
Financial health
Debt / equity โ€” โ€” โ€” โ€” โ€” 10.7x โ€”
Interest coverage โ€” โ€” โˆ’3.4x โˆ’1.9x โˆ’9.6x โˆ’6.5x โˆ’1.1x
Current ratio โ€” 1.9x 13.1x 10.9x 6.1x 7.0x 1.7x
Quick ratio โ€” 1.2x 12.6x 9.4x 5.3x 6.0x 1.4x
Capital allocation
Capex / revenue 5.3% 2.9% 4.3% 3.0% 1.0% 0.2% 0.1%
Stock comp / revenue 0.1% 0.3% 4.8% 7.8% 5.7% 8.0% 4.9%
Payouts / FCF โ€” โ€” โ€” โ€” 168.2% 0.0% 0.0%
Quality scores
Piotroski F-score โ€” โ€” 3.0 3.0 4.0 6.0 6.0
Altman Z'' โ€” โˆ’0.5 4.0 3.5 1.6 0.9 โˆ’1.9
Accruals ratio โ€” โˆ’7.5% โˆ’48.6% 13.6% โˆ’12.6% โˆ’5.6% โˆ’7.9%

Source: SEC EDGAR XBRL filings (CIK 0001818093). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open